Navigation Links
Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage,
Date:11/14/2008

Molecular Medicine, a bimonthly, biomedical journal published by The Feinstein Institute for Medical Research, strives to understand normal body functioning and disease pathogenesis at the molecular level which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. Featured in the November/December issue: “Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation”, “Angiogenesis and Diabetes: Different Responses to Pro-Angiogenic Factors in the Chorioallantoic Membrane Assay”, and “Estradiol’s Salutary Effects on Keratinocytes following Trauma-Hemorrhage Are Mediated by Estrogen Receptor (ER)- and ER-”.

(Vocus) November 14, 2008 -- Chronic Lymphocytic Leukemia (CLL) is a disease of the B lymphocytes of the immune system. Under normal conditions, B lymphocytes (or B cells) play an important role in battling infection. CLL is a disease manifested by uncontrolled growth of these B lymphocytes. In this month’s issue of Molecular Medicine, Rosa Catera and her colleagues found that CLL cells react with cells undergoing programmed cell death (apoptosis), and those with the worst outcomes have the most potent reactivity. CLL comes in several forms and has different outcomes for patients. Some can live for years or decades with few symptoms, while others progress quickly into advanced stages of disease and thus have a shorter life expectancy.

Catera and her colleagues have been trying to unravel a curious observation that many of the antibodies in CLL patients share a similar genetic sequence, no matter where in the world they live. The finding suggests that apoptosis generates substances that could stimulate CLL cell growth. In laboratory models, they have shown that this type of reactivity is seen in a small subset of B cells, suggesting that CLL might evolve from this type of normal B lymphocyte. Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation. Rosa Catera and colleagues can be reached at rcatera @ nshs.edu.

In other major news in the journal, scientists at INSERM in France have evidence that hyperglycemia impedes therapeutic angiogenesis, which could be a problem when designing ways to test these new treatment. Angiogenesis and Diabetes: Different Responses to Pro-Angiogenic Factors in the Chorioallantoic Membrane Assay Giovana Di Marco, Etienne Larger and colleagues can be reached at etienne.larger@college-de-france.fr. Scientists at the University of Alabama report stunning findings of estrogen receptor involvement in trauma and hemorrhage. Estradiol’s Salutary Effects on Keratinocytes following Trauma-Hemorrhage Are Mediated by Estrogen Receptor (ER)-± and ER-². Fariba Moeinpour, Irshad H Chaudry and colleagues can be reached at Irshad.Chaudry @ ccc.uab.edu.

To read the journal online and view this month’s popular podcast go to www.molmed.org. For more information contact Margot Puerta, managing editor of Molecular Medicine at 516-562-1129.

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1613334.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage,
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology: